VIDEO: Biologic, JAK inhibitor breakthroughs revolutionize atopic dermatitis treatment

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

It's a very exciting time now for atopic dermatitis. A very busy time also to many of us because if 10 years ago for those of us giving lectures on atopic dermatitis, we would not have practically anything to put in terms of FDA approved products or things in development. Now we have, I think one slide is not enough. You need multiple slides. So very exciting times, both in terms of the systemic molecules in development or already approved and coming.

Biologics, so we have, of course, Dupilumab already approved. We have Tralokinumab and anti IL-13 Lebrikizumab coming very shortly we are anticipating. And many in development like OX40, OX40 ligands, others. And then we have the JAK inhibitors orally and other oral molecules. So super exciting times. And also, of course, the topicals. We have a topical JAK inhibitor. We have several others that also either are coming or already approved. We have ZORYVE, the anti PDE4, and many others. Super exciting times.